Revised SPC: Calcort (deflazacort) 6mg Tablets

SPC now states tumour lysis syndrome (TLS) has been reported in patients with haematological malignancies following use of deflazacort alone or in combination with other chemotherapeutics. Patients at high risk of TLS should be monitored closely and appropriate precautions taken.

Source:

electronic Medicines compendium